Eupraxia re-elects board and re-appoints auditor at AGM
Eupraxia Pharmaceuticals Inc. re-elected all seven director nominees proposed by management at its Annual General Meeting held on June 18, 2026. Shareholders also re-appointed KPMG LLP as the company's auditor for the ensuing year and authorized the board to fix the remuneration of the auditors.

*this image is generated using AI for illustrative purposes only.
Eupraxia Pharmaceuticals Inc. re-elected all seven director nominees proposed by management at its Annual General Meeting held on June 18, 2026. The voting results confirmed the appointment of the board members, who will remain in office until the next annual meeting or until their successors are elected or appointed.
Election of Directors
All items of business were passed by the shareholders at the meeting. The election of directors was conducted via ballot vote. The detailed voting results for the seven nominees are as follows:
| Board of Directors | Votes in Favour | Votes Withheld | ||
|---|---|---|---|---|
| Number of Votes | Percentage (%) | Number of Votes | Percentage (%) | |
| James A. Helliwell | 19,815,199 | 99.784 | 42,865 | 0.216 |
| Simon Pimstone | 18,091,080 | 91.102 | 1,766,984 | 8.898 |
| Richard M. Glickman | 19,443,941 | 97.915 | 414,123 | 2.085 |
| John Montalbano | 19,470,318 | 98.047 | 387,746 | 1.953 |
| Joseph Freedman | 19,828,021 | 99.849 | 30,043 | 0.151 |
| Amy Pott | 19,828,243 | 99.850 | 29,821 | 0.150 |
| Robert Bazemore | 19,853,021 | 99.975 | 5,043 | 0.025 |
Auditor Appointment
In addition to the director elections, shareholders re-appointed KPMG LLP as the auditor of the company for the ensuing year. The resolution also authorized the board to fix the remuneration of the auditors.
What strategic priorities will the re-elected board focus on in the coming year?
How might the high shareholder approval levels influence future governance decisions?
What impact will the re-appointment of KPMG LLP have on the company's financial transparency?





















